Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OITROLC: Radiotherapy Timing in Oligometastatic Stage IV NSCLC
NCT02076477Phase 3
Key facts
- Status
- Unknown
- Start
- Jan 2014
- Primary completion
- Oct 2020
- Countries
- 1
- Sponsor
- Sichuan Cancer Hospital
- Modality
- Nanoparticles, Small Molecules
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 3, randomised, open-label trial of docetaxel, pemetrexed and Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Response Rate at 3 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Upfront CCRT
CCRT followed by 2 cycles of chemotherapy
Neoadjuvant Chemo
2 cycles of chemotherapy followed by CCRT
03
Endpoints
Primary
Response Rate
Secondary
Progression-Free Survival
Quality of Life
Grade 3-5 Esophagitis and Pneumonitis
Other Grade 3-5 Adverse Events
Beyond the preview
Go deeper on NCT02076477.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076477.